Autoanticuerpos dirigidoscontra productos de glicación avanzada en pacientes con diabetes mellitus tipo 1

Background: Advanced glycation end products are associated with chronic complications of diabetes mellitus. This glycation process renders many proteins immunogenic. Aim: To detect the presence of antibodies against albumin, collagen and low density lipoprotein glycation products in boys and teenage...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	González R,Margarita, Paquién M,Christine, Asenjo M,Sylvia, Gleisner E,Andrea, Kirsten L,Lilian, Bustamante C,Marcelo
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2001
Materias:	Antibodies Diabetes mellitus, insulin-dependent Glycosylation and products
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872001000200003
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872001000200003
record_format	dspace
spelling	oai:scielo:S0034-988720010002000032001-04-09Autoanticuerpos dirigidoscontra productos de glicación avanzada en pacientes con diabetes mellitus tipo 1González R,MargaritaPaquién M,ChristineAsenjo M,SylviaGleisner E,AndreaKirsten L,LilianBustamante C,Marcelo Antibodies Diabetes mellitus, insulin-dependent Glycosylation and products Background: Advanced glycation end products are associated with chronic complications of diabetes mellitus. This glycation process renders many proteins immunogenic. Aim: To detect the presence of antibodies against albumin, collagen and low density lipoprotein glycation products in boys and teenagers with diabetes mellitus. Patients and methods: Thirty one patients with diabetes mellitus type I, aged 11±3.8 years and with a mean duration of disease of 3.7±2.7 years and 31 healthy controls aged 12.4±5.3 years were studied. Antibodies against glycation end products were detected by ELISA and results were expressed as a ratio of the optical density of the glycated protein/optical density of the native protein. Results: Diabetic patients and healthy controls did not have antibodies against albumin glycation end products. Diabetics had higher levels of antibodies than controls for collagen glycation end products (2.6±0.4 and 1.8±0.2 respectively, p< 0.01) and low density lipoprotein glycation end products (3.07±0.92 and 2.2±0.72 respectively, p< 0.05). Conclusions: The biological role of these antibodies is not clear. They could be a depuration mechanism for glycation end products or contribute to chronic complications of diabetes mellitus (Rev Méd Chile 2001; 129: 141-48).info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.129 n.2 20012001-02-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872001000200003es10.4067/S0034-98872001000200003
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Antibodies Diabetes mellitus, insulin-dependent Glycosylation and products
spellingShingle	Antibodies Diabetes mellitus, insulin-dependent Glycosylation and products González R,Margarita Paquién M,Christine Asenjo M,Sylvia Gleisner E,Andrea Kirsten L,Lilian Bustamante C,Marcelo Autoanticuerpos dirigidoscontra productos de glicación avanzada en pacientes con diabetes mellitus tipo 1
description	Background: Advanced glycation end products are associated with chronic complications of diabetes mellitus. This glycation process renders many proteins immunogenic. Aim: To detect the presence of antibodies against albumin, collagen and low density lipoprotein glycation products in boys and teenagers with diabetes mellitus. Patients and methods: Thirty one patients with diabetes mellitus type I, aged 11±3.8 years and with a mean duration of disease of 3.7±2.7 years and 31 healthy controls aged 12.4±5.3 years were studied. Antibodies against glycation end products were detected by ELISA and results were expressed as a ratio of the optical density of the glycated protein/optical density of the native protein. Results: Diabetic patients and healthy controls did not have antibodies against albumin glycation end products. Diabetics had higher levels of antibodies than controls for collagen glycation end products (2.6±0.4 and 1.8±0.2 respectively, p< 0.01) and low density lipoprotein glycation end products (3.07±0.92 and 2.2±0.72 respectively, p< 0.05). Conclusions: The biological role of these antibodies is not clear. They could be a depuration mechanism for glycation end products or contribute to chronic complications of diabetes mellitus (Rev Méd Chile 2001; 129: 141-48).
author	González R,Margarita Paquién M,Christine Asenjo M,Sylvia Gleisner E,Andrea Kirsten L,Lilian Bustamante C,Marcelo
author_facet	González R,Margarita Paquién M,Christine Asenjo M,Sylvia Gleisner E,Andrea Kirsten L,Lilian Bustamante C,Marcelo
author_sort	González R,Margarita
title	Autoanticuerpos dirigidoscontra productos de glicación avanzada en pacientes con diabetes mellitus tipo 1
title_short	Autoanticuerpos dirigidoscontra productos de glicación avanzada en pacientes con diabetes mellitus tipo 1
title_full	Autoanticuerpos dirigidoscontra productos de glicación avanzada en pacientes con diabetes mellitus tipo 1
title_fullStr	Autoanticuerpos dirigidoscontra productos de glicación avanzada en pacientes con diabetes mellitus tipo 1
title_full_unstemmed	Autoanticuerpos dirigidoscontra productos de glicación avanzada en pacientes con diabetes mellitus tipo 1
title_sort	autoanticuerpos dirigidoscontra productos de glicación avanzada en pacientes con diabetes mellitus tipo 1
publisher	Sociedad Médica de Santiago
publishDate	2001
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872001000200003
work_keys_str_mv	AT gonzalezrmargarita autoanticuerposdirigidoscontraproductosdeglicacionavanzadaenpacientescondiabetesmellitustipo1 AT paquienmchristine autoanticuerposdirigidoscontraproductosdeglicacionavanzadaenpacientescondiabetesmellitustipo1 AT asenjomsylvia autoanticuerposdirigidoscontraproductosdeglicacionavanzadaenpacientescondiabetesmellitustipo1 AT gleisnereandrea autoanticuerposdirigidoscontraproductosdeglicacionavanzadaenpacientescondiabetesmellitustipo1 AT kirstenllilian autoanticuerposdirigidoscontraproductosdeglicacionavanzadaenpacientescondiabetesmellitustipo1 AT bustamantecmarcelo autoanticuerposdirigidoscontraproductosdeglicacionavanzadaenpacientescondiabetesmellitustipo1
_version_	1718435956058488832

Autoanticuerpos dirigidoscontra productos de glicación avanzada en pacientes con diabetes mellitus tipo 1

Ejemplares similares